Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke AUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) — XBiotech (NASDAQ: XBIT) announced today its plan to commence a randomized, placebo-controlled clinical study to test its new True Human™ antibody therapy […]